We report the case ofa prof essional scuba diver who was unable to dive beca use he began experiencing severe fronta l pain on descent. Following endoscopic surge ry to open the fron tal recess, the man was able to resume diving unrestricted by pa in. We disc uss the causes and treatment of this complaint, and we suggest that this might be conside red a new indicati on fo r surgery in a limited number of cases. ENT·Ear, Nose & Throat Journal » March 2001 e The potent antibacterial activity of CIPRO~*
Introduction
Th e front al recess is an hour glass-shaped passage between the anterior ethmo id cell s and the fro ntal sinus, with the frontal sinus ostium bein g its narrowest poin t. This recess is the ethmo id prechamb er of the fro ntal sinus. Hen ce, any disease or stenosis in this tiny area ca n lead to front al sinus infection. J With the developm ent of endoscopic sinus surgery , front al recess surgery has become one of the reco gni zed treatment s for unresolved frontal sinusitis.' However, many surgeons advise ca ution against any unnecessary surg ical int erventi on of the front al recess during routine endoscopic ethmoidectorny.' Surgery increases the risk of intracra nial and orbital complica tions, and the result ant sca rring at the fro ntal recess migh t lead to seconda ry front al sinus itis or eve n mucocele forma tio n.' Maran suggested that fro ntal recess surgery should be reser ved for more ex per ienced endoscopic sinus surgeons.'
In this article, we describe the case of a professional diver who underwent frontal recess surge ry to relieve severe divin g-related pain so that he could co ntinue in his occupation. We hope that this "ex tended" indica tion for front al recess surgery might ge nera te some thought and From discu ssion amo ng otolaryngo log ists who might see patient s who are ex pose d to "u nphysiolog ic" changes in atmos pheric pressure in the ir wor ki ng environment.
Case report
A white 19-year-old man who was a professional diver ca me to the ENT clini c in Janu ary 1999 co mplaining of severe frontal headache that occurred dur ing and follo wing each dive. He had no histor y of nasal or sinus disease and he had no nasal sy mptoms at norm al atmospheric pressure. He was a nonsm oker and his med ical history was goo d except for early chi ldhoo d as thma. His occ upation required that he perform repeated , successive dives of more than 40 meters in depth . During the previou s year, the patient began to not ice divin g-rel ated fro ntal headache. It began as a mild headache after the firs t dive and became more severe after the second dive, which prev ented him from performing a third dive . During ascent , he experienced a slight headache as he neared the surface. The pain worse ned whe n he was back on board the boat, and was part icul arly severe when he bent down . He said the pain spread "a ll ove r my hea d," and was most severe above the orbits and worse on the right side. He had bee n treated with a steroi d nasal spray by his general practitioner wit ho ut success .
We per form ed nasal endoscopy at the outpatient clinic and fo und that the patient' s nas al septum was deviated superiorly to the left, but he had no obvious abnorma lity at the lateral nasal wall. A septoplas ty was performed , but the patient' s symptoms persisted . Computed tomo graph y (CT) of the sinuses showed a muc osal thickenin g at the fro ntal recess on both sides , but the other paranasal sin uses appeared to be normal. CT also demonstrated that the uncinate process inser ted into the middle turbi nate, and the fro ntal sin us ope ned into the infundibulum (figure I). Because of conce rn that the patient' s j ob was in j eop ard y, he was offere d front al recess surgery .
Th e ope ratio n was performed under ge nera l anesthes ia. Th e uncin ate process was found to bend laterally at its superior portion and insert into the upper end of the middl e turbinate. Th e front al sinus ostium on each side was exposed by removing the entire uncin ate pro cess, including the uppermost porti on , with cutting forc ep s. Extrem e care was taken to not avulse the normal-app earing mucosa at the front al recess. Bilateral anterior ethmoidectomies we re also perform ed . The nose was packed with a small Merocel pack, which was re moved 6 hours after the opera tion. The pat ient returned to the clin ic 10 days follo wing surgery for postoperati ve nasal cleaning.
The man resumed diving 6 weeks follow ing surg ery and did not ex per ience any frontal head ache . Postoperative nasal endos copy at 6 month s revealed that the front al recesses on eac h side were wide op en and the front al sinus ostium was clearly identi fied (figure 2). Nine mo nths postoperat ivel y, the patient was still able to perform four successive dives of up to 40 meters, and to date he remains symptom-free.
Discussion
Boyle ' s law states that at a con stant temp erature , the volume of a gas is in versely proporti on al to its pressure; therefore , if the pressure of gas doubles, its volume is comp ressed in hal f. If a give n volume of gas descend s 10 meter s und er wate r, its pressure increases by I atmosphere and its volume decreases by hal f. If the container holding the gas is sea led and not elastic , there will be a relative differenc e in the internal and extern al pressure s. When this occurs in an air-filled bod y cavity, barot raum a result s.
The mo st co mmo n initia l symptom of barotr auma to the sinuses is pain, which ca n be severe and tend s to worse n with furth er descent. Pain caused by difficulty in equalizing pressure in any air-filled space-such as the sinuses, ears, and filled teeth-are well recognized in scuba diving. Divers call it a squeeze :'
Barotr auma to the paranasal sinuses is the second most common compl icati on of sport scuba divin g, behind barotr aum a to the middle ear, which is by far the most common.' Wh ile the sinus ostia remain patent, pre ssure changes in the env ironment and nasal cavities are tran smitt ed to air in the sinuses . If a patient has infected materi al in the nasal cav ity while unde rgoin g an incre ase in pressure, the infection can be forced into the sinus itse lf, thereby causi ng sinusitis. The sinuses ca n also become ob structed by tissue such as pol yps or edematous muc osa as a res ult of an upp er res piratory tract viral infecti on , allerg y, or smok ing. Anatomic varia tions-for example , an ethmoi d ce ll encro ac hing on the frontal recess-can also ob struct the ostium.' Ba rot raum a to the sinuses that occ urs only on ascent might be ca used by a ball-valve effe ct near the sinus ostia ."
Th e relative vac uum in the sinuses on descent leads to an engor gement of the blood vessels in the sinus mucosa, mucosal edema, and at its worst ble eding into the sinus. It usually affec ts the frontal and maxillary sinuses.' A reverse sinus squeeze during ascent is usuall y caused by obstruction of the ostium by redunda nt muco sa, cysts, or polyps, which lead s to overpress urizatio n of the sinuses. Th is usually cau ses only pain rather than epistax is. If the maxillary sinus is affect ed, barotrauma can caus e numbness in the region tha t is innervated by the infraorbital nerve."
Clin ical or radi olo gic exa mination might reveal the cause of the obstruc tion. In a study by Fagan et al of 50 dive rs who had experienced sinus barotr aum a, 12 (24 %) were found to have either sep tal deviation, polyps, or abnor mal nasal secre tions, and 17 (34%) reported tend erness overthe sinuses on palp ation."Oft he 43 patient s who underwent plain x-ray imagin g in the lateral, posteroanterior, and submentovertica l pos itions within 24 hours, 34 (79 %) had abnormalities in the form of fluid levels, opac ification, or muco sal thick ening see n on radiographs.
(This article had been written before CT became ava ilable.)
No authors of articles about paranasal sinus barotraum a have propo sed surgery as an appropriate treatment. Most suggest conservative management with decongestant s, but the y do not go as far as to suggest that surgery might be indicated for divers who fail to impro ve over time.
Exp erienc e confirm s the difficult y of surg ica l treatment of obstruct ion of the frontal recess." Th e imp ort ance of avo iding stenosis of the fro ntal recess was emphasized by Mosher, who wrote, "Res pect the virginity of the nasofrontal duct or take the consequences ."? Current treatment obvio usly depend s on the cause of the obstruction . Ma nage ment by endoscopic exa mination , CT, endoscopic surg ery, and postoperati ve endosco pic assess ment is now co nsidere d to be the appro priate meth od, but parana sal sinus squeeze is not generally thought of as an indicatio n for surgery.
Frontal recess surgery is regarded by many otol aryngolog ists as one of the most challeng ing areas of end osco pic sinus surgery. Th e opera tion can be mad e even more hazardou s by excess ive intra operati ve bleeding in pati ent s who have pol ypoid or inflam ed nasal muco sa. Bec ause our patient had normal nasal and sinus mucosa, we were able to maintain a relativ ely blood less field thro ughout the ope rat ion .
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